Initiation Reports


Tiziana Life Sciences: Transformational potential

Tiziana Life Sciences lead programme Foralumab is notable in that not only is this the only...

2 weeks, 6 days ago

TomCo Energy: Oil sands project moving forward

TomCo (LON:TOM) is an oil & gas exploration and production company which, operates in the...

4 weeks ago

Revive Therapeutics: Initiation report

Revive Therapeutics (CSE:RVV, OTCQB:RVVTF) is a speciality life sciences company focussed on...

on 30/6/20

Eco Equity - Growing ambition

Eco Equity has established a unique position within the fast-growing market for legal cannabis....

on 12/6/20



Primary Health Properties: Steady progress, encouraging prospects

Primary Health Properties (LON:PHP) recently announced interim results for the period to June...

6 days, 11 hours ago

Location Sciences: Reassuring trading update

Location Sciences (LON:LSAI), the world leader in location verification for mobile advertising,...

1 week, 3 days ago

MaxCyte: Firing on all cylinders

MXCT made outstanding progress in H1 20 across the business and is set to report revenue growth...

3 weeks, 1 day ago

MaxCyte: A win in gene silencing with APEIRON Biologics

MaxCyte’s new clinical and commercial licence agreement with Apeiron Biologics allows the...

4 weeks, 1 day ago

Analyst Interviews

Tiziana Life Sciences PLC's clinical plan is shaping up says analyst Emma Ulker

Proactive Research analyst Emma Ulker says Tiziana Life Sciences PLC (LON:TILS)(NASDAQ:TLSA) is driving forwards at speed with the clinical development plan for its fully-human mAb TZLS-501 COVID-19 treatment. She adds that with GMP-grade manufacturing already underway they've appointed a number...

12 hours, 11 minutes ago